Monrovia, CA, United States
Monrovia, CA, United States

Time filter

Source Type

Patent
Xencor | Date: 2016-06-17

The present invention is directed to novel heterodimeric antibodies.


Patent
Xencor | Date: 2017-03-08

The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.


The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.


Patent
Xencor | Date: 2015-06-15

The present disclosure relates to the treatment of chronic lymphocytic leukemia. Monoclonal antibody XmAb5574 is efficacious when administered to patient at certain dosage regimens. Further disclosed are regimens including said antibody is administered at least once weekly over at least eight weeks; or/and said antibody is administered at a level that achieves a total exposure to said patient measured by area under the curve (AUG) of 14,500 ug*day/ml or more.


Patent
Allergan, Inc. and Xencor | Date: 2016-12-28

The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure is related to C5 antibodies.


Patent
Xencor | Date: 2017-01-13

The present invention relates to Fc variants with optimized Fc ligand binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc ligand binding properties, and methods for using same.


Patent
Xencor | Date: 2017-04-26

The present disclosure relates to the treatment of chronic lymphocytic leukemia. Monoclonal antibody XmAb5574 is efficacious when administered to patient at certain dosage regimens. Further disclosed are regimens including said antibody is administered at least once weekly over at least eight weeks; or/and said antibody is administered at a level that achieves a total exposure to said patient measured by area under the curve (AUG) of 14,500 ug *day/ml or more.


Patent
Xencor | Date: 2017-02-01

Heterodimeric proteins including heterodimeric antibodies that bind to CD38 and CD3.


The present description relates to immunoglobulins that bind IgE and FcRIIb with high affinity, and compositions comprising said immunoglobulins being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.


The present invention relates to rapid clearance molecules that bind target antigens and FcyRIIb with increased affinity as compared to parent molecules, said compositions being capable of causing accelerated clearance of such antigens. Such compositions are useful for treating a variety of disorders, including allergic diseases, atherosclerosis, and a variety of other conditions.

Loading Xencor collaborators
Loading Xencor collaborators